Advanced Therapies Europe 2026

Advanced Therapies Europe 2026, an event organized by Phacilitate, will take place from September 7 to 9, 2026, in Barcelona, Spain.

The opportunity to participate in a key event that brings together European leaders in advanced therapies, as well as experts, developers, and regulators, to discuss the latest developments in the research, development, and commercialization of cellular, gene, and regenerative therapies should not be missed.

Advanced Therapies Europe provides a unique platform for collaboration, knowledge exchange, and the creation of synergies that drive the future of personalized and innovative medicine.

The topics of interest at Advanced Therapies Europe include biotechnology investment, focusing on opportunities for startups and investors, as well as women's leadership and inclusivity in the sector. Key discussions will cover the scaling and production of gene and cell therapies, particularly in AAV manufacturing, and the European regulations and regulatory challenges. Additionally, important topics such as patient access to treatments and the industrialization of cell therapies will be addressed, aiming to overcome barriers to their clinical implementation.

Whether you are launching a new therapy, seeking strategic partnerships, or aiming to anticipate regulatory and market changes, Advanced Therapies Europe is designed to provide you with practical insights and meaningful connections.

• Expand your network – Meet CEOs from biotechnology, pharmaceutical strategists, CDMO leaders, and investors who are shaping the next wave of therapeutic innovation.
• Gain strategic perspective – Access expert-led industry sessions on regulation, funding trends, scaling solutions, and commercial strategy.
• Discover what lies ahead – Explore the latest advances in cell and gene therapy platforms, biotechnological technologies, and regenerative medicine.

On July 15 at 2 pm, Advanced Therapies Europe is organising the webinar “Europe’s ATMP Roadmap: From Strategy to Execution in a New Global Reality”, a pre-event session to discuss Europe’s challenges in innovation, manufacturing and clinical trials in advanced therapies.

Montse Daban, Director of Strategy and Global Partnerships at Biocat, will take part alongside Miguel Forte, CEO of Kiji Therapeutics, and Paolo Morgese, VP Public Affairs Europe at the Alliance for Regenerative Medicine.

07/09/2026

09:15h - 09:55h | Workshop Room

What it takes to fund advanced therapies in 2026

• Artemy Shumskiy, Principal - LongeVC
• Gadareth Higgs, Partner - Advantary Capital Partners
• Laura Rodriguez, Partner - Invivo Partners
• Malgorzata Rogalska, Analyst - Ysios Capital

• Rahul Khetan, Venture Associate - UCB Ventures

   

09:55h - 10:35h | Workshop Room

Panel: Alternative funding models and capital structures for biotech

• Claudio Santos, CEO - Gyala Therapeutics

   

10:50h - 11:30h | Workshop Room

Differentiation or bust: How to stand out in a saturated market

• Francisca Peixoto, Co-Founder and Managing Partner - LifeLink Ventures
• Jose Mesa, Partner - Columbus Venture Partners

• Marc Ramis Castelltort, Founder & Managing Partner - Montana

   

11:30h - 12:00h | Workshop Room

Fireside Chat: What “investment ready” looks like in 2026

• Avencia Sanchez-Mejias, CEO & Co-Founder - Integra Therapeutics
• Luis Pareras, Managing Partner - Invivo Partners

08/09/2026

09:05h - 09:45h | Theatre 1&2

Europe’s ATMP rulebook reset: The 12-month pathway from fragmented rules to trusted EU execution

• Esteve Trias, Executive Medical Director and Technical Director of Advanced Therapies Unit - Hospital Clínic de Barcelona

• Sean Russell, Managing Partner - PrimeRA Pharma Partners

   

10:20h - 11:00h | Theatre 1&2

Winning the next wave of ATMP R&D: What Europe must resolve to compete on speed, scale and return

• Miguel Forte, CEO - Kiji Therapeutics
• Montse Daban, Director of Strategic Foresight and International Relations - BIOCAT
• Paolo Morgese, Vice President Public Affairs, Europe - Alliance for Regenerative Medicine

12:00h - 12:30h | Theatre 1

CGT clinical trials at pace: What’s accelerating, what’s stuck and how Europe turns trials into treatments

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra
• Esther Kitto, VP Clinical Operations - Resolution Therapeutics
• Joana Claverol, Head of Clinical Research Unit - Sant Joan de Deu

• Manel Juan Otero, Head of Immunology - Hospital Clínic de Barcelona

   

16:15h - 17:15h

When venture philanthropy meets venture creation | Workshop Room

• Gonzalo Fernandez-Miranda, Co-founder & CEO - CureAge Therapeutics

09/09/2026

10:30h - 11:15h |  Theatre 1&2

Designing CGTs in the age of agentic AI: How to accelerate discovery and development without losing regulatory control

• Aneta Tyszkiewicz, Director Data Digital - EFPIA - European Federation of Pharmaceutical Industries and Associations
• Clara Cuervo, Head of AI and Digital Transformation Cell Therapy Clinical Operations Global - AstraZeneca
• Marc Guell, Cofounder & Scientific Head - Integra Therapeutics

• Vasiliki Kalodimou, Assistant Professor - European University Cyprus

   

10:30h - 11:15h |  Theatre 1

Panel: Access is the real innovation: How Europe turns breakthroughs into therapies patients can actually receive

• Alessandra Magnani, Head of Advanced Therapies and Immunotherapy Platform - Hospital Sant Joan de Déu 
• Marion Hitchcock, Managing Director Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager - Bayer
• Stefanos Theoharis, CEO - OneChain Immunotherapeutics

Companies and entities in the BioRegion of Catalonia can enjoy a 20% discount by using the code BIOCAT20 at the time of registration.